Long Ideas - Last week, the FDA accepted Navidea Biopharmaceuticals’ (NASDAQ:NAVB) resubmitted New Drug Application for Lymphoseek and set an April 30 PDUFA goal. Navidea’s submission was met … Continue Reading
Read NowLong Ideas - Ziopharm (NASDAQ:ZIOP) recently announced that its Independent Data Monitoring Committee (IDMC) looked at the rate of events in the phase III trial and now expects … Continue Reading
Read NowLong Ideas - On Friday November 9th, Celgene (NASDAQ:CELG) released top-line data from its phase III 1st-line metastatic pancreatic cancer trial and noted that the study met its … Continue Reading
Read NowLong Ideas - Puma Biotechnology (NYSE:PBYI) made waves last month when it uplisted to the NYSE and initiated a substantial capital raise, increasing cash and equivalents to approximately … Continue Reading
Read NowLong Ideas - Against a backdrop of growing opioid abuse in the U.S., Endo Health Solutions (NASDAQ:ENDP) announced another step Monday night in its efforts to curb abuse … Continue Reading
Read NowLong Ideas - The biotechnology sector is one where growth is, for the most part, fueled by a single factor: new drugs. Companies that develop the next generation … Continue Reading
Read NowLong Ideas - Intermezzo prescriptions are slowly growing, says Transcept management, but royalty revenue has yet to make a substantial contribution to Transcept Pharmaceuticals’ (NASDAQ:TSPT) top-line. For the third quarter, … Continue Reading
Read Now